Onkologie. 2023:17(2):95-100 | DOI: 10.36290/xon.2023.020

Personalized therapy in pancreatic cancer

Marián Liberko^{1, 2}, Renata Soumarová^{1, 2}

¹ Onkologická klinika 3. LF UK a FNKV, Praha

² 3. lékařská fakulta Univerzity Karlovy, Praha

Pancreatic cancer is a disease with increasing incidence and mortality worldwide. Current standard of treatment is chemotherapy regardless of clinical stage. Despite improvements in survival thanks to multi-agent regimens in adjuvant, neoadjuvant and paliative setting, pancreatic cancer still has the worst prognosis across all malignancies. Oncology nowadays is more or less personalized/precise. With help of NGS we are able to identify specific subtypes of patients with pancreatic cancer, which have both, different prognosis and require specific approach to treatment. The aim of this review is to provide information about pancreatic cancer as a molecularly heterogeneous disease, which require personalized approach. Main part of review is about pancreatic cancer with defects in DDR/HRD system with an option for more or less personalized therapy with platinum derivatives, followed in some cases with maintenance with PARP inhibitors. Smaller molecularly defined subgroups are described briefly, because of smaller amount of data from the literature.

Keywords: pancreatic cancer, personalized therapy, molecular subtypes, mtKRAS, wtKRAS.

Accepted: April 26, 2023; Published: April 27, 2023  Show citation